RATIONALE: Delta-9-tetrahydrocannabinol (THC) is one of the few cannabinoid receptor ligands that can be used to probe the cannabinoid system in humans. Despite increasing interest in the cannabinoid receptor system, use of intravenous THC as a research tool has been limited by concerns about its abuse liability and psychoactive effects. OBJECTIVES: This study aims to evaluate the safety of all intravenous THC studies conducted at this center for the past 13 years. METHODS: Included were 11 studies with 266 subjects (14 schizophrenia patients and 252 healthy subjects, of whom 76 were frequent cannabis users), 351 active THC infusions, and 226 placebo infusions. Subjects were monitored for subjective and physical adverse events and followed up to 12 months beyond study participation. RESULTS: There was one serious and 70 minor adverse events in 9.7% of subjects and 7.4% of infusions, with 8.5% occurring after the end of the test day. Nausea and dizziness were the most frequent side effects. Adverse events were more likely to be associated with faster infusion rates (2-5 min) and higher doses (>2.1 mg/70 kg). Of 149 subjects on whom long-term follow-up data were gathered, 94% reported either no change or a reduction in their desire to use cannabis in the post-study period, 18% stated that their cannabis use decreased, and 3% stated that it increased in the post-study period. CONCLUSIONS: With careful subject selection and screening, risk to subjects is relatively low. Safeguards are generally sufficient and effective, reducing both the duration and severity of adverse events.
RCT Entities:
RATIONALE: Delta-9-tetrahydrocannabinol (THC) is one of the few cannabinoid receptor ligands that can be used to probe the cannabinoid system in humans. Despite increasing interest in the cannabinoid receptor system, use of intravenous THC as a research tool has been limited by concerns about its abuse liability and psychoactive effects. OBJECTIVES: This study aims to evaluate the safety of all intravenous THC studies conducted at this center for the past 13 years. METHODS: Included were 11 studies with 266 subjects (14 schizophreniapatients and 252 healthy subjects, of whom 76 were frequent cannabis users), 351 active THC infusions, and 226 placebo infusions. Subjects were monitored for subjective and physical adverse events and followed up to 12 months beyond study participation. RESULTS: There was one serious and 70 minor adverse events in 9.7% of subjects and 7.4% of infusions, with 8.5% occurring after the end of the test day. Nausea and dizziness were the most frequent side effects. Adverse events were more likely to be associated with faster infusion rates (2-5 min) and higher doses (>2.1 mg/70 kg). Of 149 subjects on whom long-term follow-up data were gathered, 94% reported either no change or a reduction in their desire to use cannabis in the post-study period, 18% stated that their cannabis use decreased, and 3% stated that it increased in the post-study period. CONCLUSIONS: With careful subject selection and screening, risk to subjects is relatively low. Safeguards are generally sufficient and effective, reducing both the duration and severity of adverse events.
Authors: J H Krystal; I L Petrakis; E Webb; N L Cooney; L P Karper; S Namanworth; P Stetson; L A Trevisan; D S Charney Journal: Arch Gen Psychiatry Date: 1998-04
Authors: Deepak Cyril D'Souza; Walid Michel Abi-Saab; Steven Madonick; Kimberlee Forselius-Bielen; Anne Doersch; Gabriel Braley; Ralitza Gueorguieva; Thomas B Cooper; John Harrison Krystal Journal: Biol Psychiatry Date: 2005-03-15 Impact factor: 13.382
Authors: Emma Barkus; Paul D Morrison; D Vuletic; John C Dickson; Peter J Ell; Lyn S Pilowsky; Rudolf Brenneisen; David W Holt; John Powell; Shitij Kapur; Robin M Murray Journal: J Psychopharmacol Date: 2010-09-17 Impact factor: 4.153
Authors: P D Morrison; V Zois; D A McKeown; T D Lee; D W Holt; J F Powell; S Kapur; R M Murray Journal: Psychol Med Date: 2009-04-01 Impact factor: 7.723
Authors: Jose Cortes-Briones; Patrick D Skosnik; Daniel Mathalon; John Cahill; Brian Pittman; Ashley Williams; R Andrew Sewell; Mohini Ranganathan; Brian Roach; Judith Ford; Deepak Cyril D'Souza Journal: Neuropsychopharmacology Date: 2015-04-24 Impact factor: 7.853
Authors: Deepak Cyril D'Souza; Daniel J Fridberg; Patrick D Skosnik; Ashley Williams; Brian Roach; Nagendra Singh; Michelle Carbuto; Jacqueline Elander; Ashley Schnakenberg; Brian Pittman; R Andrew Sewell; Mohini Ranganathan; Daniel Mathalon Journal: Neuropsychopharmacology Date: 2012-02-15 Impact factor: 7.853
Authors: R Andrew Sewell; Ashley Schnakenberg; Jacqueline Elander; Rajiv Radhakrishnan; Ashley Williams; Patrick D Skosnik; Brian Pittman; Mohini Ranganathan; D Cyril D'Souza Journal: Psychopharmacology (Berl) Date: 2012-11-24 Impact factor: 4.530